ASH 2018 | CD79b-specific CAR T-cell therapy: overcoming treatment resistance in B-cell lymphoma

Sattva Neelapu

Here, Sattva Neelapu, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the utilization of CD79b-specific CAR T-cells for targeting CAR T-cell therapy resistance due to loss of CD19 in B-cell lymphomas. Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA., Prof. Neelapu reveals the preclinical results that suggest targeting CD79b could be a novel strategy to overcome this resistance.

Share this video  
Similar topics